#USA #Lancaster #Lung Cancer #Avmacol #Sulforaphane

Groundbreaking Clinical Study on Avmacol®

A recently published clinical study conducted by Nutramax Laboratories, reveals promising results regarding the use of Avmacol®, a supplement designed to promote cellular health. The research focuses on its effects in former smokers who are at an elevated risk for lung cancer, particularly analyzing the modulation of Ki-67 markers, which are crucial indicators of cancer cell proliferation.

Study Overview

The study, which was led by Dr. Jian-Min Yuan from the University of Pittsburgh Medical Center Hillman Cancer Center, was published in Cancer Prevention Research. In this double-blind, placebo-controlled trial, 43 former smokers were randomly assigned to receive either Avmacol® or a placebo for a duration of 12 months. The participants in the Avmacol® group consumed 120 milligrams of glucoraphanin, the primary ingredient responsible for producing sulforaphane, a compound known for its detoxifying and antioxidant properties.

Key Findings

The results were striking; those taking Avmacol® exhibited a 20% decrease in Ki-67 levels, while the placebo group saw an alarming 65% increase. This significant difference underscores the potential role of Avmacol® in reducing markers associated with cancer proliferation in high-risk individuals.

Dr. Yuan emphasized, "The promising results from this phase II clinical trial provide support for a phase III intervention trial with a large sample size to directly examine the efficacy of lung cancer prevention by sulforaphane." Such findings could pave the way for more extensive studies and potential therapeutic avenues in cancer prevention strategies.

Importance of Sulforaphane

Sulforaphane has garnered attention over the years due to its numerous health benefits, particularly in relation to detoxification and maintaining cellular health. It is produced naturally in the body when glucoraphanin combines with the enzyme myrosinase. The study reinforces Avmacol® as a key player in enhancing sulforaphane levels in the body, making it a leading choice for those looking to bolster their health, especially former smokers.

Meghan Hamrock, MS, MPH, Director of Consumer Marketing and Clinical Nutrition at Nutramax Laboratories, explained, "This study adds to the rich body of scientific evidence in understanding the nutritional benefits of sulforaphane for targeted care in complex cases, further establishing Avmacol® as the most researched sulforaphane-producing brand."

Looking Forward

With the success of this study, Nutramax Laboratories is gearing up to expand their clinical efforts. Future research will focus on the long-term impacts of Avmacol® and its potential to prevent lung cancer in a wider audience. The company remains dedicated to its mission of enhancing consumer health through innovative, research-backed supplements.

About Nutramax Laboratories

Nutramax Laboratories Consumer Care, Inc., established in 1992, is a Christian-based organization committed to producing high-quality, effective health products. Recognized for its groundbreaking research, Nutramax develops nutritional supplements such as Cosamin®, the top researched glucosamine/chondroitin sulfate brand, and Avmacol®, leading the market in sulforaphane-producing brands based on peer-reviewed studies. Their headquarters is located in Lancaster, South Carolina, employing over 800 personnel nationwide.

For more information on Avmacol® and its health benefits, visit Avmacol.com or contact customer service at 888-886-6442.